Clinical Outcome of Hyperuricemia in IgA Nephropathy: A Retrospective Cohort Study and Randomized Controlled Trial | Zendy

Yongjun Shi | Zendy; Wei Chen | Zendy; Diana Jalal | Zendy; Zhibin Li | Zendy; Wenfang Chen | Zendy; Haiping Mao | Zendy; Qiong Yang | Zendy; Richard J. Johnson | Zendy; Xueqing Yu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Outcome of Hyperuricemia in IgA Nephropathy: A Retrospective Cohort Study and Randomized Controlled Trial

Author(s) -

Yongjun Shi,

Wei Chen,

Diana Jalal,

Zhibin Li,

Wenfang Chen,

Haiping Mao,

Qiong Yang,

Richard J. Johnson,

Xueqing Yu

Publication year - 2011

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000331453

Subject(s) - hyperuricemia , medicine , allopurinol , renal function , nephropathy , blood pressure , proteinuria , kidney disease , urology , uric acid , retrospective cohort study , randomized controlled trial , gastroenterology , kidney , endocrinology , diabetes mellitus

Hyperuricemia is an independent risk factor for renal progression in IgA nephropathy (IgAN). However, no study has evaluated the effect of allopurinol on the clinical outcome in hyperuricemic IgAN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research